You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
STTR Phase I: Biodegradable Electronic Sensors to Measure Environmental Data for Perishable Goods
SBC: TRANSPARENT PATH SPC Topic: IThe broader impact / commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to minimize food waste, reduce electronic sensor waste, and develop a printed, biodegradable, electronic sensor. According to the United Nations, food waste is valued at $2.4 trillion/year worldwide with the majority of the expense attributed to transport. Electronic waste is approximatel ...
STTR Phase I 2023 National Science Foundation -
Analyzing Nutritional Benefits of Micronized Defatted Berry Seed Powders Using an in-vitro Model of the Human Gut Microbiome
SBC: Nutraberry LLC Topic: 85Not able to read summary file
STTR Phase I 2023 Department of Agriculture -
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
SBC: Metselex, Incorporated Topic: 105ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells
SBC: MARPAM PHARMA LLC Topic: NIAIDProject Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Two-for-one Stroke Thrombectomy:A novel Dual DAC to enhance navigability, lumen size, aspiration efficiency, and persistent flow arrest in mechanical thrombectomy
SBC: PIRAEUS MEDICAL, INC. Topic: 105PROJECT SUMMARY/ABSTRACT The long-term goal of this proposal is to improve the care of patients suffering from Large Vessel Occlusion Acute Ischemic stroke. Currently, mechanical thrombectomy techniques can achieve revascularization in over 70% of cases, and physicians are rapidly adoption aspiration thrombectomy over stent-trievers. Aspiration maintains equivalent angiographic and clinical outcom ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting Myosin to Treat Polycystic Kidney Disease
SBC: PLUREXA LLC Topic: 400PROJECT SUMMARY The goal of this proposal is to advance a new therapeutic approach targeting myosin for polycystic kidney disease (PKD). PKD is a major life-threatening Mendelian disorder that affects 12,000,000 individuals, representing a market opportunity of ~$1 billion. In PKD, tiny tubules in the kidneys, liver, and other organs gradually expand into fluid-filled cysts, leading to organ failu ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)
SBC: SMART INFORMATION FLOW TECHNOLOGIES LLC Topic: NHGRIPROJECT SUMMARY Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the U ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis
SBC: KULEANA TECHNOLOGY, INC. Topic: 400PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics
SBC: MYRIEL, INC. Topic: 105PROJECT ABSTRACT Myriel, Inc., is a pharmaceutical start-up company founded in 2022 to find cures for tauopathies, including Alzheimer’s disease and related dementias (ADRD), which impair cognition in 32% of US adults 65 years and older. The goal of this Phase 1 STTR application is to provide Myriel with a brain-penetrant analogue of our lead compound, GPHR ‘739, the first potent, selective, r ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.
SBC: GELBCHEM, LLC Topic: NICHDProject Summary The goal of this project is to design and prepare diagnostic biomarker reference standards for the endogenous glycosaminoglycan (GAG) Mucopolysaccharidosis type I (MPS-I) and type II (MPS- II) biomarkers. MPS-I and MPS-II are lysosomal storage disorders (LSDs) which are listed on the Recommended Uniform Screening Panel (RUSP) in the United States and are included in global Newborn ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health